Sign in to use this feature.

Years

Between: -

Subjects

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Journals

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Article Types

Countries / Regions

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Search Results (3,770)

Search Parameters:
Keywords = metabolic dysregulation

Order results
Result details
Results per page
Select all
Export citation of selected articles as:
25 pages, 9628 KB  
Article
A Synbiotic of Lacto-N-tetraose and Bifidobacterium animalis subsp. lactis MN-Gup Attenuates High-Fat Diet-Induced Obesity by Modulating Metabolism and Gut Microbiota in Mice
by Ying Luo, Yang Li, Linjun Wu, Xiaoqiong Li, Xiangyu Bian, Jian Kuang, Jianqiang Li, Fangshu Shi, Xuguang Zhang, Xiaoqiang Han, Jinzhu Pang, Jinjun Li and Haibiao Sun
Nutrients 2026, 18(11), 1681; https://doi.org/10.3390/nu18111681 (registering DOI) - 24 May 2026
Abstract
Background/Objectives: Obesity is closely associated with gut microbiota dysbiosis, intestinal barrier dysfunction, and impaired glucose and lipid metabolism. However, single probiotic or prebiotic interventions often yield only limited metabolic improvements. This study aimed to evaluate the effects of a synbiotic formulation comprising Lacto- [...] Read more.
Background/Objectives: Obesity is closely associated with gut microbiota dysbiosis, intestinal barrier dysfunction, and impaired glucose and lipid metabolism. However, single probiotic or prebiotic interventions often yield only limited metabolic improvements. This study aimed to evaluate the effects of a synbiotic formulation comprising Lacto-N-tetraose (LNT) and Bifidobacterium animalis subsp. lactis MN-Gup (MN-Gup) in a high-fat diet (HFD)-induced obese mouse model. Methods: In this study, an HFD-induced obese mouse model was used to investigate whether the synbiotic formulation of LNT and MN-Gup could ameliorate obesity-related metabolic dysregulation, intestinal barrier dysfunction, and gut microbiota imbalance. Mice were treated with LNT alone, MN-Gup alone, or the synbiotic at different doses. Serum biochemical parameters, glucose tolerance, lipid profiles, liver histopathology, intestinal barrier markers, gut microbiota composition, short-chain fatty acid (SCFA) levels were analyzed. Results: High-dose synbiotic intervention significantly outperformed single-component treatments in reducing weight gain, improving glucose tolerance and lipid profiles, and attenuating hepatic lipid accumulation and injury in mice. These metabolic changes were accompanied by improved markers of intestinal barrier integrity and modulation of gut microbiota composition, characterized by the enrichment of beneficial genera (e.g., Akkermansia, Leuconostoc, and Alistipes) alongside a reduction in obesity-associated taxa (including Desulfovibrionaceae_unclassified, Colidextribacter, Helicobacter, Erysipelatoclostridium, Peptococcaceae_unclassified, and Firmicutes_unclassified). Spearman correlation analysis revealed associative links between microbial alterations and host metabolic markers. Conclusions: Collectively, these findings suggest that the synbiotic formulation comprising high-dose LNT and MN-Gup offers potential benefits for managing high-fat diet-induced metabolic dysregulation in mice. Full article
15 pages, 541 KB  
Review
Copper Metabolism in Isolated Macrophages: Regulator of Immunity and Inflammation
by Xinao Leng, Ping Yu, Zhidi Xu, Chenglong Xia, Rui Du, Qiwen Luo, Yanqiu Zhu and Hongrui Guo
Vet. Sci. 2026, 13(6), 511; https://doi.org/10.3390/vetsci13060511 (registering DOI) - 24 May 2026
Abstract
Copper is essential for the proper functioning of immune cells and participates in diverse biochemical processes. The maintenance of copper ion homeostasis is critical for normal host physiology, while dysregulation of copper metabolism is closely linked to various diseases. Emerging evidence indicates that [...] Read more.
Copper is essential for the proper functioning of immune cells and participates in diverse biochemical processes. The maintenance of copper ion homeostasis is critical for normal host physiology, while dysregulation of copper metabolism is closely linked to various diseases. Emerging evidence indicates that disease-associated elevations in copper levels significantly enhance macrophage functions, including the expression of inflammatory cytokines, phagocytosis, and bactericidal activity. As key innate immune cells, macrophages not only eliminate invading pathogens but also contribute to immune regulation, tissue repair, and angiogenesis. In this review, we summarize current knowledge of copper transport and homeostatic mechanisms in macrophages and highlight how copper regulates their antimicrobial activity, inflammatory responses, and reparative functions. A deeper understanding of these mechanisms may provide new insights into therapeutic strategies targeting macrophage regulation through copper metabolism in the context of infectious and inflammatory diseases. Full article
Show Figures

Figure 1

26 pages, 2546 KB  
Review
NMDA Receptor Mediated Mechanisms in the Post-Stroke Brain: From Physiology to Pathology
by Han Gong, Xiang-Zheng Wang, Dan Liu, Wei-Jin Liu, Xiao-Xia Du and Jia-Sheng Rao
Biomolecules 2026, 16(6), 770; https://doi.org/10.3390/biom16060770 (registering DOI) - 23 May 2026
Abstract
N-methyl-D-aspartate receptors (NMDARs) play a context-dependent role in ischemic stroke (IS), contributing to acute excitotoxic injury while also supporting subsequent neuroplasticity. This functional divergence has constrained the therapeutic efficacy of non-selective NMDAR antagonists. During the acute phase, neuronal injury is associated with the [...] Read more.
N-methyl-D-aspartate receptors (NMDARs) play a context-dependent role in ischemic stroke (IS), contributing to acute excitotoxic injury while also supporting subsequent neuroplasticity. This functional divergence has constrained the therapeutic efficacy of non-selective NMDAR antagonists. During the acute phase, neuronal injury is associated with the redistribution of NMDARs toward extrasynaptic sites and the activation of aberrant non-ionotropic signaling pathways. As the disease progresses, NMDAR-dependent signaling becomes increasingly involved in activity-dependent plasticity, including motor engram consolidation, dendritic remodeling, and large-scale network reorganization. Post-stroke cognitive impairment and depression are increasingly recognized as potential consequences of sustained NMDAR dysregulation, involving interactions with immune signaling and metabolic processes. These observations support a shift toward activity-dependent modulation of NMDAR function, in which neurotoxic signaling is selectively dissociated from physiological receptor activity. Emerging strategies aimed at subunit-specific modulation and disruption of pathological receptor complexes provide a basis for more targeted intervention. Preservation of physiological excitation–inhibition balance may therefore represent a key requirement for optimizing functional recovery after stroke. Full article
Show Figures

Figure 1

14 pages, 899 KB  
Article
Anemia-Driven Phenotypes in Lung Cancer: Linking Inflammation and Sarcopenia
by Claudia Raluca Mariean, Oana Mirela Tiucă, Cristina Flavia Al-Akel, Sofia Teodora Muntean, Diana Maria Chiorean and Ovidiu Simion Cotoi
Diagnostics 2026, 16(11), 1600; https://doi.org/10.3390/diagnostics16111600 (registering DOI) - 23 May 2026
Abstract
Background/Objectives: Lung cancer remains a leading cause of cancer-related mortality and is characterized by complex tumor–host interactions, including systemic inflammation, metabolic dysregulation, and immune imbalance. This study aimed to evaluate whether a diagnosis of anemia reflects underlying inflammatory burden and to explore [...] Read more.
Background/Objectives: Lung cancer remains a leading cause of cancer-related mortality and is characterized by complex tumor–host interactions, including systemic inflammation, metabolic dysregulation, and immune imbalance. This study aimed to evaluate whether a diagnosis of anemia reflects underlying inflammatory burden and to explore phenotype-based interactions between anemia, inflammation, and muscle depletion in lung cancer patients. Methods: A retrospective cohort study was conducted, including 70 patients diagnosed with lung cancer between 2019 and 2023. Anemia was defined using standard hemoglobin thresholds (<12 g/dL in women, <13 g/dL in men). Systemic inflammation was assessed using complete blood count-derived indices (NLR, PLR, SII, SIRI, and AISI), both individually and combined into a cumulative inflammatory score. Sarcopenia was evaluated through CT-based quantification of skeletal muscle area at the L3 level. Patients were stratified into four phenotypes based on anemia status, inflammatory burden, and sarcopenia. Statistical analyses like Mann–Whitney U, Kruskal–Wallis with Dunn post hoc testing, and univariate logistic regression were used. Results: Anemia was present in 44.3% of patients and was associated with a significantly higher inflammatory score compared to non-anemic patients (median 5 [IQR 4–5] vs. 4 [3–5], p = 0.024). Among inflammatory markers, PLR was significantly associated with anemia (OR = 4.94, 95% CI: 1.57–15.52, p = 0.004). The cumulative inflammatory score showed a non-significant association with anemia (OR = 1.28, 95% CI: 0.93–1.75, p = 0.124). Phenotype-based analysis revealed significant differences in skeletal muscle area (p = 0.004), with the sarcopenic-inflammatory phenotype exhibiting significantly lower muscle mass compared to other groups. No associations were observed between phenotypes and tumor stage or histological subtype. Conclusions: Anemia in lung cancer patients is closely associated with systemic inflammation and may reflect underlying biological vulnerability rather than tumor-specific characteristics. A phenotype-based approach integrating anemia, inflammatory markers, and sarcopenia provides a more comprehensive understanding of disease heterogeneity and may improve risk stratification. Further studies are needed to validate these findings and assess their prognostic implications. Full article
(This article belongs to the Special Issue Recent Advances in the Diagnosis and Prognosis of Lung Cancer)
Show Figures

Figure 1

43 pages, 1800 KB  
Review
Research Progress on the Role of Traditional Chinese Medicine in Regulating Ferroptosis in Cardiovascular Diseases
by Pan Li, Zi-Meng Qi, Shi-Chang Li, Jin-Ling Liang, Tian-Yang Xu and Peng Yu
Biology 2026, 15(11), 824; https://doi.org/10.3390/biology15110824 (registering DOI) - 23 May 2026
Abstract
Ferroptosis is an iron-dependent form of regulated cell death driven by lipid peroxidation, playing a critical role in the pathogenesis of various cardiomyopathies, including hypertrophic, dilated, diabetic, ischemic, doxorubicin-induced, and septic cardiomyopathy, as well as myocardial ischemia–reperfusion injury. This article provides a comprehensive [...] Read more.
Ferroptosis is an iron-dependent form of regulated cell death driven by lipid peroxidation, playing a critical role in the pathogenesis of various cardiomyopathies, including hypertrophic, dilated, diabetic, ischemic, doxorubicin-induced, and septic cardiomyopathy, as well as myocardial ischemia–reperfusion injury. This article provides a comprehensive narrative review of the molecular mechanisms of ferroptosis—centered on dysregulation of the GPX4/System Xc axis, iron metabolism, and lipid metabolism—and its role in cardiovascular diseases, with a specific focus on the cardioprotective effects of Traditional Chinese Medicine (TCM). Through a systematic analysis of recent literature, we highlight active components (e.g., baicalin, ginsenoside Rg3, resveratrol, tanshinone IIA), compound formulations (e.g., Qishen Granule, Zhilong Huoxue Tongyu Capsule), and electroacupuncture therapy, which exert effects via multi-target regulation of ferroptosis-related pathways such as Nrf2/HO-1/GPX4, p53/SLC7A11, and PI3K/AKT. Evidence indicates that TCM interventions effectively alleviate cardiomyocyte ferroptosis by activating the Nrf2 antioxidant pathway to upregulate GPX4/SLC7A11, modulating iron metabolism to reduce labile iron pools, and inhibiting ACSL4/ALOX15-mediated lipid peroxidation, with these effects validated in diverse cardiovascular disease models showing improved cardiac function. Targeting ferroptosis offers a novel therapeutic strategy for cardiovascular diseases, and TCM—with its synergistic multi-component, multi-target, multi-pathway advantages—holds significant potential in this context. Future research should prioritize elucidating complex network mechanisms and advancing clinical translation via high-quality studies to provide new theoretical foundations and drug candidates for cardiovascular disease management. Full article
(This article belongs to the Section Biochemistry and Molecular Biology)
17 pages, 1642 KB  
Review
The Glutamate–Glutamine Axis in Pediatric Septic Shock: Immunometabolic Mechanisms, Biomarker Potential, and Clinical Implications
by Yaru Cui, Juan Wang and Yiyao Bao
Int. J. Mol. Sci. 2026, 27(11), 4708; https://doi.org/10.3390/ijms27114708 (registering DOI) - 23 May 2026
Abstract
Pediatric septic shock remains a major cause of morbidity and mortality in critically ill children and is increasingly recognized as a syndrome of profound immunometabolic dysregulation. This narrative review synthesizes current clinical, translational, and mechanistic evidence on the glutamate–glutamine axis in pediatric septic [...] Read more.
Pediatric septic shock remains a major cause of morbidity and mortality in critically ill children and is increasingly recognized as a syndrome of profound immunometabolic dysregulation. This narrative review synthesizes current clinical, translational, and mechanistic evidence on the glutamate–glutamine axis in pediatric septic shock. The review focuses on how glutamine and glutamate metabolism may interact with immune-cell function, mitochondrial substrate handling, redox defense, and intestinal barrier integrity, while distinguishing biological plausibility from validated clinical utility. Current evidence supports the glutamate–glutamine axis as a mechanistically relevant pathway and a source of candidate biomarkers, but pediatric-specific data remain limited and do not yet justify routine biomarker use or glutamine-based intervention in unselected children with septic shock. Future studies should use standardized sampling, reproducible analytical methods, pediatric validation cohorts, and phenotype-guided trial designs before this axis can be translated into clinical decision making. Full article
Show Figures

Figure 1

23 pages, 34239 KB  
Article
miRNA-Mediated Signaling Networks in Non-Small Cell Lung Cancer: Linking Tumor Progression to Sarcopenia
by Swati Goswami, Pooja Gulhane and Shailza Singh
Int. J. Mol. Sci. 2026, 27(11), 4703; https://doi.org/10.3390/ijms27114703 (registering DOI) - 23 May 2026
Abstract
Non-small cell lung cancer (NSCLC) remains a major cause of cancer-related mortality, with poor survival outcomes despite advances in surgery, chemotherapy, targeted therapy, and immunotherapy. The tumor microenvironment (TME) plays a central role in sustaining tumor growth, immune evasion, and systemic metabolic dysfunction. [...] Read more.
Non-small cell lung cancer (NSCLC) remains a major cause of cancer-related mortality, with poor survival outcomes despite advances in surgery, chemotherapy, targeted therapy, and immunotherapy. The tumor microenvironment (TME) plays a central role in sustaining tumor growth, immune evasion, and systemic metabolic dysfunction. In this study, we performed an integrative analysis of differentially expressed microRNAs (miRNAs) to uncover their contributions to dysregulated signaling networks in NSCLC. hsa-miR-486-5p was identified as a prominent differentially expressed candidate miRNA. Using mathematical modeling and regression-based reduction, we identified Forkhead Box O1 (FOXO1) and Unc-51 like Autophagy Activating Kinase 2 (ULK2) as critical regulatory nodes that integrate oncogenic signaling with cellular homeostasis. Aberrant expression of hsa-miR-486-5p was found to modulate pathways including PI3K/AKT/mTOR, NF-κB, and JAK-STAT3, thereby promoting tumor progression and secretion of inflammatory cytokines. These cytokines, viz., IL-6, TNF-α, and IL-1β, activate muscle-specific protein degradation pathways through E3 ubiquitin ligases TRIM63 and FBXO32, linking NSCLC progression to cancer-associated sarcopenia. Quasipotential landscape analysis further revealed dynamic phenotypic transitions between stable and unstable states, highlighting the adaptability of tumor–host interactions. Collectively, our findings demonstrate that miRNA-mediated regulatory networks not only drive NSCLC progression and inflammation but also contribute to systemic muscle wasting. These insights emphasize the need for novel therapeutic strategies, including RNA-based interventions, to overcome resistance, improve survival, and address the metabolic complications associated with NSCLC. Full article
Show Figures

Graphical abstract

25 pages, 1056 KB  
Review
Amino Acid–Fatty Acid Profile as a Novel Predictive Method in the Assessment of Diagnosis and Treatment Efficacy of Anxiety-Related Disorders and Mood Disorders
by Mateusz Kowalczyk, David Aebisher, Jakub Szpara, Sara Czech, Edward Kowalczyk, Ireneusz Majsterek, Dorota Bartusik-Aebisher and Gabriela Henrykowska
Int. J. Mol. Sci. 2026, 27(11), 4705; https://doi.org/10.3390/ijms27114705 (registering DOI) - 23 May 2026
Abstract
Major depressive disorder (MDD) and anxiety disorders are increasingly understood as conditions involving complex metabolic dysregulation across multiple biological domains. This review aimed to synthesize current clinical and translational evidence on amino acid metabolism, lipid metabolism and short-chain fatty acids (SCFAs) as potential [...] Read more.
Major depressive disorder (MDD) and anxiety disorders are increasingly understood as conditions involving complex metabolic dysregulation across multiple biological domains. This review aimed to synthesize current clinical and translational evidence on amino acid metabolism, lipid metabolism and short-chain fatty acids (SCFAs) as potential biomarkers, and components of integrative metabolic profiling in these disorders. A structured narrative approach was applied, focusing on studies assessing metabolomic alterations, their clinical correlates and their potential role in patient stratification, and treatment response. The available evidence indicates that amino acid disturbances, particularly within the tryptophan–kynurenine pathway, represent the most consistent and clinically interpretable findings. Lipid-related alterations, especially involving long-chain polyunsaturated fatty acids, provide complementary insights into membrane function, inflammation and neuroplasticity. In contrast, SCFAs appear to function as context-dependent markers rather than robust standalone biomarkers, with their clinical relevance depending on biological matrix, metabolic context and host–microbiota interactions. Importantly, most studies assess individual metabolites rather than integrated metabolic profiles, limiting their interpretability within a metabolomic framework. Overall, current evidence supports a shift toward integrative biomarker models that combine metabolic data with selected molecular and clinical parameters. Future research should focus on standardized, reproducible profiling approaches to enable biologically informed stratification and personalized treatment strategies. Full article
Show Figures

Figure 1

21 pages, 1901 KB  
Article
Metabolomics-Enhanced Liquid Biopsy Identifies Early Heptocellular Injury in Females with MetALD
by Anika Volkmar, Gregor Mattert, Florian Deisinger, Kornelius Schulze, Asmus Heumann, Werner Dammermann, Selina Strathmeyer, Steffen Heelemann, Thomas Kalinski, Stefan Lüth and Janine Kah
Int. J. Mol. Sci. 2026, 27(11), 4695; https://doi.org/10.3390/ijms27114695 (registering DOI) - 22 May 2026
Abstract
Steatotic liver disease (SLD) is characterised by profound metabolic reprogramming, yet no single biomarker reliably distinguishes disease entities, stages or sex-specific risk profiles. By integrating serum metabolomic signatures as a liquid biopsy with tumour-associated CSC marker profiles in a sex-stratified analytical framework, we [...] Read more.
Steatotic liver disease (SLD) is characterised by profound metabolic reprogramming, yet no single biomarker reliably distinguishes disease entities, stages or sex-specific risk profiles. By integrating serum metabolomic signatures as a liquid biopsy with tumour-associated CSC marker profiles in a sex-stratified analytical framework, we aimed to identify biologically meaningful differences and improve strategies for early, presymptomatic detection of SLD progression and HCC. The present study focuses on a targeted panel of 12 strongly dysregulated serum metabolites as candidate biomarkers of disease progression, quantified by NMR-based metabolomics and ELISA and complemented by CSC marker staining. We combined these NMR-based metabolomic ‘liquid biopsy’ data with circulating tumour-associated biomarkers, MELD-based risk assessment and tissue-level CSC marker expression across MetALD, MASLD, immune-mediated and cancerogenic liver disease, HCC and healthy controls. Female MetALD patients showed the second highest mortality after HCC, with lower survival than male cancer patients, despite MELD 3.0 assigning ~50% higher scores in women. MetALD mortality clustered with GP73, CD44, metabolomics and AA/3HB ratio, indicating a distinct, high-risk female phenotype. Integrating liquid-based metabolomic profiling, AA/3HB redox assessment, CSC markers and MELD 3.0 into sex-sensitive diagnostic pathways may improve early detection and risk stratification of alcohol-associated SLD, especially in women. Full article
Show Figures

Figure 1

18 pages, 1192 KB  
Article
The Proteomics-Based Stratification of Obese Subjects Allows for a Second Selective Level Beyond Gender Classification
by Raffaello Viganò, Jonica Campolo, Francesca Brambilla, Dario Di Silvestre, Ettore Corradi, Marina Parolini, Cinzia Dellanoce, Patrizia Tarlarini, Paolo Iadarola, Francesco Scaglione and Pierluigi Mauri
Int. J. Mol. Sci. 2026, 27(11), 4678; https://doi.org/10.3390/ijms27114678 - 22 May 2026
Abstract
Obesity is a major global health challenge characterized by chronic low-grade inflammation, oxidative stress, and an increased risk of cardiometabolic disorders. Although sex-related differences in inflammatory and redox biomarkers have been reported in obese populations, the molecular mechanisms underlying this heterogeneity remain incompletely [...] Read more.
Obesity is a major global health challenge characterized by chronic low-grade inflammation, oxidative stress, and an increased risk of cardiometabolic disorders. Although sex-related differences in inflammatory and redox biomarkers have been reported in obese populations, the molecular mechanisms underlying this heterogeneity remain incompletely understood. In this study, we applied a proteomics-based approach to investigate urinary extracellular vesicles from 45 obese individuals (BMI 30–40 kg/m2; age 50–70 years) in order to identify molecular signatures associated with metabolic dysregulation. Shotgun proteomics analysis performed by nanoLC–MS/MS enabled the identification of 3822 proteins. Hierarchical clustering of proteomic profiles revealed two distinct molecular groups, predominantly enriched in males (Group I) and females (Group II). Label-free quantitative analysis identified 466 differentially abundant proteins between the two clusters. Functional enrichment analysis highlighted pathways associated with immune response, metabolic regulation, and redox homeostasis, including glycolysis/gluconeogenesis, lysosome activity, leukocyte transendothelial migration, and glutathione, cysteine and methionine metabolism. Notably, proteins related to ferroptosis were enriched, suggesting the involvement of iron-dependent oxidative cell death mechanisms in the metabolic imbalance observed in a subset of subjects. Furthermore, the non-enzymatic glycosylation of urinary proteins was significantly higher in Group I compared with Group II (p = 0.0002), indicating increased formation of advanced glycation products in individuals with a more pronounced pro-oxidant state. Preliminary follow-up data suggested a higher incidence of pathological events, including cardiovascular complications, among individuals belonging to Group I. Overall, these findings demonstrate that urinary proteomic profiling can identify distinct molecular phenotypes among obese individuals and highlight oxidative stress, ferroptosis, and protein glycation as potential determinants of metabolic vulnerability, supporting the use of non-invasive proteomic approaches for improved risk stratification in obesity. Full article
23 pages, 1658 KB  
Review
Mitochondrial Dysfunction in Traumatic Brain Injury and Its Theranostic Implications
by Vratko Himic, Nana Tchantchaleishvili, Andrii Netliukh, Salvatore Chibbaro, Nikolaos Syrmos, Gianfranco K. I. Ligarotti, Lara Prisco and Mario Ganau
Biomolecules 2026, 16(6), 762; https://doi.org/10.3390/biom16060762 - 22 May 2026
Abstract
Background: Traumatic brain injury (TBI) remains a major cause of neurological morbidity and mortality. Mitochondria, being embedded as one of the key organelles disrupted after injury, play a central role in regulating neuronal metabolism, oxidative balance, and cell survival, hence the growing interest [...] Read more.
Background: Traumatic brain injury (TBI) remains a major cause of neurological morbidity and mortality. Mitochondria, being embedded as one of the key organelles disrupted after injury, play a central role in regulating neuronal metabolism, oxidative balance, and cell survival, hence the growing interest in their role after TBI. Methods: We present a narrative review of the literature on mitochondrial dysfunction after TBI to highlight the potential role in diagnosis, monitoring, prognostication and treatment strategies. Following SANRA guidelines we conducted a synthesis of 159 selected references published between 1997 and 2026, including 70 references published from 2020 onward. Results: Mitochondrial dysfunction underpins bioenergetic failure through the impairment of critical regulatory pathways, including oxidative phosphorylation, dysregulated reactive oxygen species production, and dysregulated calcium handling. These changes trigger downstream processes of oxidative damage, epigenetic and proteomic remodeling, and activation of regulated cell death pathways such as apoptosis, necroptosis, and ferroptosis in the context of an inflammatory milieu. As such, mitochondrial-derived molecules (such as mitochondrial DNA and microRNA) are emerging candidate biomarkers of TBI severity and prognosis. Additionally, therapeutic approaches under investigation include inhibition of the mitochondrial permeability transition pore, mitigation of mitochondrial oxidative stress using targeted antioxidants, restoration of NAD+-dependent metabolic pathways, and metabolic support through ketogenic interventions. Conclusions: Mitochondrial biology is advancing our understanding of TBI and offers a promising framework for improving its management. Full article
(This article belongs to the Special Issue Mitochondria and Central Nervous System Disorders: 3rd Edition)
Show Figures

Figure 1

16 pages, 1686 KB  
Article
Reduced Circulating MOTS-c Levels in Hashimoto’s Thyroiditis Reflect Integrated Autoimmune and Metabolic Dysregulation: A Cross-Sectional Study
by Hanişe Ozkan Sonay, Eda Nur Duran, Murvet Algemi, Berrak Sahtiyanci, Irem Kirac Utku, Esra Çokiçli, Naile Fevziye Misirlioglu, Gonul Simsek, Hafize Uzun and Omur Tabak
J. Clin. Med. 2026, 15(11), 4002; https://doi.org/10.3390/jcm15114002 - 22 May 2026
Abstract
Background: Hashimoto’s thyroiditis (HT) is a common autoimmune disorder characterized by chronic inflammation and metabolic alterations. Mitochondria-derived peptides (MDPs), particularly mitochondrial open-reading frame of the 12S rRNA-c (MOTS-c), have emerged as key regulators of cellular metabolism, insulin sensitivity, oxidative stress, and inflammatory [...] Read more.
Background: Hashimoto’s thyroiditis (HT) is a common autoimmune disorder characterized by chronic inflammation and metabolic alterations. Mitochondria-derived peptides (MDPs), particularly mitochondrial open-reading frame of the 12S rRNA-c (MOTS-c), have emerged as key regulators of cellular metabolism, insulin sensitivity, oxidative stress, and inflammatory responses. This study aimed to investigate the association between circulating MOTS-c levels and HT and to explore its potential role in thyroid autoimmunity and metabolic regulation. Methods: In this cross-sectional study, patients diagnosed with HT (n: 90) were compared with age- and sex-matched healthy controls (n: 90). Results: A total of 180 participants were included, comprising 90 patients with HT and 90 age- and sex-matched healthy controls. Circulating MOTS-c levels were significantly lower in patients with HT compared to controls (p < 0.001). MOTS-c levels demonstrated significant inverse correlations with body mass index, fasting glucose, HbA1c, HOMA-IR, thyroid-stimulating hormone, C-reactive protein, and thyroid autoantibody levels (all p < 0.05). In subgroup analyses, these associations remained significant within the HT cohort, particularly for HOMA-IR and thyroid autoantibodies. Multivariable regression analysis identified HT (β = −30.04, p < 0.001) and HOMA-IR (β = −0.85, p < 0.001) as independent determinants of reduced circulating MOTS-c levels. Levothyroxine (LT4) use was not associated with significant differences in MOTS-c concentrations. Conclusions: Circulating MOTS-c levels are markedly reduced in patients with HT and are independently associated with insulin resistance and autoimmune burden. These findings suggest that impaired mitochondrial signaling may play a role in the pathophysiology of thyroid autoimmunity and highlight MOTS-c as a promising biomarker linking metabolic dysfunction and immune dysregulation. Full article
(This article belongs to the Section Endocrinology & Metabolism)
Show Figures

Figure 1

22 pages, 1920 KB  
Review
O-GlcNAcylation as a Metabolic Integrator in Cardiovascular Physiology and Disease
by Saima Shakil Malik, Xinchun Pi and Liang Xie
Int. J. Mol. Sci. 2026, 27(11), 4662; https://doi.org/10.3390/ijms27114662 - 22 May 2026
Abstract
O-GlcNAcylation is a ubiquitous post-translational modification regulated by O-GlcNAcase (OGA) and O-GlcNAc transferase (OGT) in response to environmental and genetic alterations. It occurs in the nucleus, mitochondrion, and cytoplasm and is implicated in cardiovascular disease (CVD) development. O-GlcNAcylation modulates [...] Read more.
O-GlcNAcylation is a ubiquitous post-translational modification regulated by O-GlcNAcase (OGA) and O-GlcNAc transferase (OGT) in response to environmental and genetic alterations. It occurs in the nucleus, mitochondrion, and cytoplasm and is implicated in cardiovascular disease (CVD) development. O-GlcNAcylation modulates diverse cellular processes, including metabolic pathways, signaling networks, and transcriptional programs. Acute increase in O-GlcNAcylation serves as an adaptive response that preserves cardiac function, whereas chronic elevation leads to persistent metabolic dysregulation and promotes pathological cardiac remodeling. In this review, we provide a comprehensive overview of the role of O-GlcNAcylation across diverse disease contexts. We also summarize the current understanding of its complex interplay with CVD, including the underlying mechanisms. Finally, we highlight existing knowledge gaps and discuss the therapeutic potential of targeting O-GlcNAcylation in various cardiovascular events, emphasizing key priorities for future research. Full article
(This article belongs to the Section Molecular Endocrinology and Metabolism)
Show Figures

Figure 1

21 pages, 5160 KB  
Article
Prophylactic and Therapeutic Anti-Hyperglycemic Effects of Heat-Killed Mycobacterium aurum in STZ-Induced Diabetic Mice
by Ali Ali, Hanin-Khaula Hakam, Alaa Eter, Samer Bazzi, Amani Chahine, Charles Akle, Georges M. Bahr and Karim S. Echtay
Nutrients 2026, 18(11), 1652; https://doi.org/10.3390/nu18111652 - 22 May 2026
Abstract
Background/Objectives: Exploiting the metabolic properties of postbiotics is a novel strategy for managing metabolic disorders, including diabetes. Inactivated microorganisms, a major class of postbiotics, improve glycemic control in preclinical and clinical studies. Here, we examined whether heat-killed (HK) Mycobacterium aurum (M. [...] Read more.
Background/Objectives: Exploiting the metabolic properties of postbiotics is a novel strategy for managing metabolic disorders, including diabetes. Inactivated microorganisms, a major class of postbiotics, improve glycemic control in preclinical and clinical studies. Here, we examined whether heat-killed (HK) Mycobacterium aurum (M. aurum) exerts prophylactic or therapeutic anti-hyperglycemic effects in diabetic mice. Methods: Diabetes was induced in male BALB/c mice by streptozotocin (STZ; 150 mg/kg) injection. HK M. aurum (1 mg) was given orally (three prophylactic doses before STZ) or intradermally (six weekly therapeutic doses after STZ). We assessed glycemic parameters, serum C-peptide/insulin (ELISA), and tissue protein expression (Western blot). Results: Neither route altered body weight or glucose homeostasis in non-diabetic mice. In STZ-diabetic mice, oral prophylactic treatment significantly attenuated hyperglycemia (39–60% reduction weeks 5–8 post-STZ) and showed a trend toward improved serum C-peptide, but did not affect dysregulated expression of skeletal muscle (SM), hepatic, pancreatic and renal proteins involved in glucose transport (GLUT2, GLUT4, and SGLT2), glycolysis (α-LDH), mitochondrial uncoupling (UCP2 and UCP3), and antioxidant defense (CAT). Therapeutic intradermal administration significantly decreased blood glucose (~30% at week 5, ~40% at week 6) and modestly enhanced insulin secretion. Hepatic UCP2 and α-LDH and SM UCP3 protein levels were normalized toward non-diabetic levels, whereas hepatic GLUT2 and SM GLUT4 remained largely unchanged. These correlative findings suggest effects independent of insulin-dependent glucose transport, but do not demonstrate direct functional improvement in mitochondrial or redox status. Conclusions: HK M. aurum exerts partial anti-hyperglycemic effects in STZ-induced diabetic mice, but the associated protein changes require functional validation before its role as a postbiotic in β-cell dysfunction can be established. Full article
Show Figures

Figure 1

20 pages, 1090 KB  
Review
Extraintestinal Manifestations of Inflammatory Bowel Disease: A Focus on Kidney Complications
by Hao Wu, Aiping Lin, Jingshu Chi, Jing Zhang, Bo Peng, Dan Ni, Hong Hao and Zhenguo Liu
Int. J. Mol. Sci. 2026, 27(10), 4614; https://doi.org/10.3390/ijms27104614 - 21 May 2026
Viewed by 83
Abstract
Inflammatory bowel disease (IBD), comprising Crohn’s disease (CD) and ulcerative colitis (UC), is a chronic relapsing–remitting condition characterized by systemic and intestinal inflammation and immune dysregulation. Up to 47% of IBD patients develop extraintestinal manifestations, yet kidney and urological involvement remain underrecognized. Accumulating [...] Read more.
Inflammatory bowel disease (IBD), comprising Crohn’s disease (CD) and ulcerative colitis (UC), is a chronic relapsing–remitting condition characterized by systemic and intestinal inflammation and immune dysregulation. Up to 47% of IBD patients develop extraintestinal manifestations, yet kidney and urological involvement remain underrecognized. Accumulating evidence has linked IBD to nephrolithiasis, glomerular diseases, tubulointerstitial nephritis, acute kidney injury, chronic kidney disease, and, rarely, amyloid A amyloidosis. Population studies have consistently shown elevated risks for various important kidney disorders in IBD, with CD generally posing a greater risk than UC. The pathogenesis of kidney complications in IBD reflects complex gut–kidney interactions, including metabolic and absorptive abnormalities, shared genetic and immune pathways, intestinal dysbiosis with nephrotoxic microbial metabolites, systemic inflammation, and drug-related nephrotoxicity. Strategies for kidney protection in IBD include increased awareness, close monitoring of kidney function, urinary metabolic profiling in high-risk patients, and prompt nephrology referral for early detection and treatment. Management should include an effective and sustained control of intestinal inflammation, discontinuation of potential nephrotoxic drugs when indicated, and timely diagnosis and treatment of kidney manifestations, as well as integrating kidney complications into IBD guidelines to enhance awareness, ultimately optimizing both the kidney and overall outcomes for IBD patients. Future studies are needed to validate the potential predictive biomarkers for kidney complications and to develop targeted interventions to address shared gut–kidney pathogenic mechanisms in IBD. Full article
(This article belongs to the Section Molecular Endocrinology and Metabolism)
Show Figures

Figure 1

Back to TopTop